ZSB BMO Short Term Bond Index ETF

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that the clinical trial, for novel anti-aging compound TFC-1326, started on December 5th, 2022.

The trial, which will take place in Paris, is designed to assess the compound’s efficacy in reversing aging facial skin, including restoring lost volume (plumping) and reducing fine wrinkles. The formulation is a cream base with TFC-1326 at a concentration of 1% and no other active ingredients.

The trial design was done with the assistance of a leading organization in commercial aesthetics. It will consist of 20 participants, aged 40-65 with specific signs of aging. Participants will begin in weeks 1 through 3 as a rolling start and continue for a 12-week period using the product twice daily. Ten parameters will be measured using advanced technology. These include skin radiance, skin laxity, antioxidant analysis, anti-inflammation, wrinkles, skin plumping and product tolerance. The clinical trial is fully financed, owned and controlled by Sirona.

“We’re very excited to have this study underway. We’ve been conducting R&D on the anti-aging project for many years and have seen amazing efficacy and unique activity in cell studies. To make the transition to human skin will be a major achievement for the company and the science team in France,” said Dr. Howard Verrico, CEO. “The incredible work that has been done so far has shown that these compounds are unlike anything else available on the market today. They have the ability to actually increase the level of fat in the skin by generating lipid growth. The effect should be a plumping of the skin, which will improve the look of sagging and wrinkles. They also have shown to have many other properties we believe will help to reverse and protect the ongoing effects of aging on the skin.”

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.

For more information regarding this press release, please contact:

Investor Enquiries:Jonathan WilliamsManaging DirectorMomentum PRPhone: 1.450.332.6939Email: jwilliams@momentumpr.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.